Real‐world use of idarucizumab for dabigatran reversal in three cases of serious bleeding
نویسندگان
چکیده
Bleeding is a rare complication of direct oral anticoagulant potentially associated with high mortality rates. Biological monitoring is necessary for more than 24 h after idarucizumab antidote therapy in case of bleeding with dabigatran therapy.
منابع مشابه
The Use of Idarucizumab for Dabigatran Reversal in Clinical Practice: A Case Series.
PURPOSE To describe the use of idarucizumab (Praxbind, Boehringer Ingelheim) in routine clinical practice at a large urban academic medical center. SUMMARY Seven total doses of idarucizumab were administered to six unique patients from October 31, 2015, to October 31, 2016. The reversal agent was used in conjunction with local bleeding control measures, blood product transfusions, and acid-su...
متن کاملIdarucizumab for Reversal of Dabigatran-Associated Bleeding: Misnomer or Miracle?
BACKGROUND The development of novel oral anticoagulants (NOACs) has revolutionized oral anticoagulation. Rapid incorporation of NOACs into general practice has heightened the demand for directed reversal agents. Idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran. While it is a welcome addition to reversal strategies of d...
متن کاملReversal of Dabigatran Using Idarucizumab in a Septic Patient with Impaired Kidney Function in Real-Life Practice
Background. Immediate reversal of anticoagulation is essential when facing severe bleeding or emergency surgery. Although idarucizumab is approved for the reversal of dabigatran in many countries, clinical experiences are lacking, particularly in special patient-populations such as sepsis and impaired renal function. Case Presentation. We present the case of a 67-year-old male septic patient wi...
متن کاملTowards the development of specific antidotes: Idarucizumab for reversal of dabigatran effects.
http://dx.doi.org/10.1160/TH15-04-0324 Thromb Haemost 2015; 114: 1162–1163 Despite the proven efficacy of novel oral anticoagulants, bleeding still remains a serious complication (1–3). In case of lifethreatening conditions, immediate reversal of the anticoagulant effect is needed, regardless of the relatively short-half life of new direct anticoagulants. However, there is a lack of experience ...
متن کاملDabigatran reversal with idarucizumab in a patient undergoing heart transplantation: first European report
BACKGROUND Dabigatran is a direct thrombin inhibitor with a favorable effectiveness and safety profile when compared to vitamin K antagonists, both in randomized trials and real world registries of atrial fibrillation patients. Yet, physicians' fear of high bleeding risk scenarios in daily clinical practice still precludes a more widespread use of oral anticoagulation. We hereby report a succes...
متن کامل